Peptide & Longevity Research
Plain-language summaries of peer-reviewed studies, reviewed by Dr. Patrick Taylor, MD. Educational only, not medical advice.
Semaglutide & Tirzepatide Reduce Fall and Femoral Fracture Risk in Older Adults with Type 2 Diabetes (2026)
A 2026 TriNetX study finds semaglutide and tirzepatide cut fall risk by ~34% and femoral fracture risk by ~51% vs. DPP-4 inhibitors in older diabetic adults.
Tirzepatide vs. Semaglutide Neuropsychiatric Safety: What a 2026 Real-World Study Reveals
A large 2026 real-world study finds tirzepatide and semaglutide carry comparable neuropsychiatric risk profiles, with semaglutide outperforming older GLP-1 RAs.
Tirzepatide for Type 1 Diabetes and Obesity: Real-World Results Show Major Glycemic and Weight Benefits (2026)
A 2026 real-world study found tirzepatide significantly reduced HbA1c, weight by 13.4 kg, and improved cardiometabolic markers in type 1 diabetes patients.
Peptide Detection in Dried Blood Spots: What the 2026 Analytical Workflow Study Means for Patients
A 2026 Ghent University study validated a fast LC-HRMS method detecting 54 peptides in dried blood spots, revealing key stability data for BPC-157 and more.
BPC-157 Protects Against Ischemia-Reperfusion Injury: 2026 Research Summary
New rat study shows BPC-157 reduces oxidative stress, apoptosis, and inflammation in lower limb ischemia-reperfusion injury. Learn what this means for peptide therapy.
GLP-1 Receptor Agonist Switching Patterns 2018–2025: What Semaglutide Persistence Data Means for Peptide Therapy Patients
A 42,000-patient study reveals 30% of GLP-1 RA users switch agents—learn what therapy-specific switching rates mean for your semaglutide treatment plan.
Semaglutide for Dumping Syndrome & Reactive Hypoglycemia After Bariatric Surgery: 2026 Research Summary
A 2026 meta-analysis finds semaglutide significantly reduces dumping syndrome symptoms and hypoglycemic episodes in post-bariatric surgery patients.
GLP-1 Peptide Therapy & Lean Mass Preservation: Key Nutrition Findings (2026)
New research outlines protein strategies and micronutrient monitoring to protect lean muscle during GLP-1 peptide therapy. Dr. Taylor reviews the findings.
Therapeutic Peptides for Healthy Aging: What a 2026 Gerontology Review Means for Patients
A 2026 Frontiers in Aging review examines 9 therapeutic peptides targeting aging hallmarks. Learn what the evidence says about safety and efficacy.
Semaglutide Protects the Liver Beyond Weight Loss: What New 2026 Research Reveals
A 2026 Cell Metabolism study shows semaglutide improves liver disease through GLP-1 receptors on liver endothelial cells, independent of weight loss.
Peptide Therapy for Musculoskeletal Injuries: Safety & Efficacy Review (2026)
A 2026 Sports Medicine review examines approved and unapproved peptides like BPC-157 and sermorelin for injury recovery and athletic performance.
Semaglutide for MASH: RCT Shows FAST Score & MRI-PDFF Improvements (2026)
New RCT data shows semaglutide 2.4 mg significantly reduces FAST score, liver fat, and ALT in at-risk MASH patients. Key findings for peptide therapy candidates.
A Phase 2 Randomized Trial of Retatrutide in People with Obesity and MASLD
Retatrutide achieved normalization of liver fat (<5%) in up to 90% of participants with metabolic-associated steatotic liver disease (MASLD) at 48 weeks.
Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Comparator-Controlled, Parallel-Group, Phase 2 Trial
Retatrutide at the highest dose achieved HbA1c reductions of up to 2.02% and body weight reductions of up to 16.9% at 36 weeks in patients with type 2 diabetes, outperforming dulaglutide.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Retatrutide produced dose-dependent weight reductions up to 24.2% at 48 weeks in adults with obesity, with 100% of participants in the highest-dose group achieving at least 5% weight loss.
Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial
GHRH analog treatment reduced visceral fat by 20%, improved triglyceride-to-HDL ratio, and increased growth hormone and IGF-1 levels without worsening glucose tolerance.
Tesamorelin, a Growth Hormone-Releasing Factor Analogue, Improves Visceral Adiposity and Metabolic Parameters in HIV-Infected Patients
Phase 3 trial showed tesamorelin reduced trunk fat by 15.4% and visceral fat by 27.8% at 26 weeks, with significant increases in IGF-1 and improvements in patient-reported body image.
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
Tesamorelin significantly reduced visceral adipose tissue by 15.2% versus a 5% increase with placebo over 26 weeks, with concurrent improvements in triglycerides and cholesterol ratios.
Glutathione and its antiaging and antimelanogenic effects
Oral glutathione at just 250 mg/day for 12 weeks significantly reduced melanin index, UV spots, and wrinkles while improving skin elasticity — with both reduced and oxidized forms showing benefits.
Glutathione and immune function
Established that lymphocytes require balanced intracellular glutathione levels for optimal function, and even moderate GSH changes profoundly affect immune cell activity — with GSH repletion nearly completely restoring NK cell function in deficient patients.
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function
Liposomal glutathione raised whole blood GSH by 40% within just 2 weeks, increased NK cell cytotoxicity up to 400%, and reduced oxidative stress markers by 35%.
Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment
Long-term NAC treatment (a glutathione precursor) dramatically reduced influenza symptoms — only 25% of infected NAC-treated subjects developed symptoms versus 79% on placebo — while shifting cell-mediated immunity from anergy to normal function.
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
High-dose oral glutathione (1,000 mg/day) significantly increased blood and tissue GSH levels by 30-35% and more than doubled natural killer cell cytotoxicity versus placebo in a 6-month randomized controlled trial.
Thymosin beta4 promotes matrix metalloproteinase expression during wound repair
Showed that thymosin beta-4 accelerates wound healing by upregulating matrix metalloproteinases (MMP-1, MMP-2, MMP-9), which are essential enzymes for tissue remodeling and repair.
Thymosin beta4 is cytoprotective in human gingival fibroblasts
Demonstrated that thymosin beta-4 protects gingival fibroblasts from chemical damage, suppresses inflammatory IL-8 secretion, and prevents apoptosis — confirming its broad cytoprotective capabilities.
Stable gastric pentadecapeptide BPC 157-NO-system relation
Demonstrated that BPC-157 modulates the nitric oxide system to promote healing across multiple tissue types, with effects on vascular responses, gene expression, and gastric protection.
BPC 157 and blood vessels
Identified BPC-157 as the most potent angiomodulatory agent studied, acting through multiple vasoactive pathways including nitric oxide, VEGF, and focal adhesion kinase signaling.
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing
Demonstrated that BPC-157 stimulates angiogenesis by upregulating VEGF expression in muscle and tendon injuries, directly improving tissue repair through new blood vessel formation.
The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline
Showed that GHK modulates approximately 31% of human genes relevant to nervous system function, with effects on neuroprotection, DNA repair, and antioxidant defense that may help address cognitive decline.
The human tri-peptide GHK and tissue remodeling
Established that GHK-Cu activates comprehensive tissue remodeling processes including cellular recruitment, collagen and elastin synthesis, nerve growth factor production, and wound healing.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Revealed that GHK-Cu regulates approximately 31.2% of human genes, with broad effects on tissue regeneration, antioxidant defense, DNA repair, and anti-cancer activity.
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Demonstrated that BPC-157 provides neuroprotection across multiple models including traumatic brain injury, spinal cord compression, and peripheral nerve regeneration, while modulating dopaminergic and serotonergic systems.
Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke
Demonstrated Semax's angioprotective and antihypoxic properties during acute ischemic stroke, with a key mechanism involving the shift from pro-inflammatory to anti-inflammatory cytokine balance.
The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
Genome-wide analysis revealed Semax predominantly enhances immune-related gene expression and modifies vascular development genes during brain ischemia, explaining its broad neuroprotective mechanism.
Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
Demonstrated that Semax selectively activates transcription of BDNF, TrkC, and TrkA neurotrophins in ischemic brain cortex, providing targeted neuroprotective gene activation after stroke.
Possible Role of Transthyretin in the Biological Mechanism of the Regulatory Peptide Neuroprotection
Discovered that Semax dramatically altered transthyretin gene expression during brain ischemia, identifying a novel neuroprotective pathway through which the peptide may protect the brain during stroke.
Stress, kisspeptin, and functional hypothalamic amenorrhea
Established kisspeptin dysfunction as a key mechanism in stress-related loss of menstrual periods, supporting kisspeptin therapy as a targeted treatment for functional hypothalamic amenorrhea.
REPRODUCTIVE TOXICOLOGY: Impact of endocrine disruptors on neurons expressing GnRH or kisspeptin and pituitary gonadotropins
Revealed that environmental endocrine disruptors can harm kisspeptin neurons, underscoring the importance of supporting kisspeptin signaling to protect reproductive health in an increasingly toxic environment.
The kisspeptin-GnRH pathway in human reproductive health and disease
Provided a definitive review of kisspeptin's role in human reproductive health and disease, establishing the evidence base for kisspeptin as a therapeutic agent for infertility and reproductive disorders.
A dual kisspeptin-GnRH immunogen for reproductive immunosterilization
Demonstrated the potent biological activity of the kisspeptin-GnRH system through an immunization approach, confirming the powerful influence kisspeptin has on reproductive hormone regulation.
The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction
Comprehensively confirmed kisspeptin's central role as the master regulator of the reproductive hormone axis, supporting its therapeutic potential for fertility and hormonal health.
Heterogeneity in GnRH and kisspeptin neurons and their significance in vertebrate reproductive biology
Revealed important diversity among kisspeptin neuron populations, advancing understanding of how different kisspeptin circuits control distinct aspects of reproductive function.
Kisspeptin and GnRH interactions in the reproductive brain of teleosts
Provided important insights into the conserved interaction between kisspeptin and GnRH across vertebrate species, confirming kisspeptin's fundamental role as a master regulator of reproductive function.
The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism
Demonstrated that MOTS-c protects against radiation-induced lung injury through its antioxidant properties, revealing a powerful tissue-protective effect mediated by the Nrf2 pathway.
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress
Discovered that MOTS-c travels from mitochondria to the cell nucleus to directly regulate gene expression during metabolic stress, revealing a remarkable new pathway for cellular communication.
The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus
Showed that MOTS-c effectively reduces high blood sugar and insulin resistance in gestational diabetes, demonstrating its therapeutic potential for pregnancy-related metabolic conditions.
Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination
Demonstrated that MOTS-c can suppress ovarian cancer progression through a novel molecular mechanism, expanding the peptide's therapeutic potential beyond metabolic health into oncology.
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Demonstrated for the first time that MOTS-c promotes metabolic balance, reduces obesity, and reverses insulin resistance, establishing it as a powerful metabolic regulator.
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Highlighted MOTS-c's wide-ranging therapeutic potential across metabolic, cardiovascular, and age-related conditions, positioning it as one of the most versatile mitochondrial-derived peptides.
Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases
Provided a comprehensive overview of MOTS-c's protective effects against diabetes and aging-related diseases, confirming its role as a key mitochondrial signaling peptide for metabolic health.
ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development
Showed that NNMT is upregulated during liver stress and directly contributes to fatty liver disease, supporting NNMT inhibition as a therapeutic strategy for liver health.
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Demonstrated that inhibiting NNMT in cancer-associated fibroblasts restores the immune system's ability to fight tumors, revealing a powerful new role for NNMT inhibitors beyond metabolic health.
Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis
Uncovered the cellular mechanisms driving adipose tissue fibrosis in obesity, revealing new therapeutic targets for restoring healthy fat tissue function and improving metabolic outcomes.
The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function
Revealed that adipose tissue function and fat distribution are more important predictors of metabolic health than total fat mass, supporting targeted metabolic interventions for obesity management.
Relevance of body composition in phenotyping the obesities
Demonstrated that body composition analysis is essential for properly classifying obesity subtypes, supporting personalized metabolic interventions that target fat quality rather than just quantity.
Obesity and hypertension
Demonstrated the strong mechanistic link between obesity and hypertension, supporting the rationale for metabolic interventions that reduce fat accumulation to improve cardiovascular outcomes.
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
Established that obesity phenotypes vary widely in metabolic risk, highlighting how targeted fat metabolism interventions like NNMT inhibition could address the specific metabolic dysfunction driving cardiovascular disease.
Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry
Validated analytical methods for TB-500 detection, reflecting the peptide's recognized potency for tissue repair and recovery that has driven widespread interest in its therapeutic applications.
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
Characterized the active fragment of thymosin beta-4 in TB-500, confirming its molecular identity and providing foundational data on its potent tissue-repair bioactivity.
AOD-9604 does not influence the WADA hGH isoform immunoassay
Confirmed that AOD-9604 operates independently from growth hormone pathways, supporting its favorable safety profile as a targeted fat-metabolism peptide without systemic GH effects.
A method for confirming CJC-1295 abuse in equine plasma by LC-MS/MS
Advanced analytical methods confirmed CJC-1295's potent and long-lasting biological activity, further validating its effectiveness as a growth hormone secretagogue.
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Developed a highly sensitive detection method for CJC-1295, underscoring the peptide's significant biological potency and sustained growth hormone-releasing activity.
Bremelanotide
Comprehensive pharmacological profile of bremelanotide confirmed its efficacy and safety as an innovative melanocortin-based therapy for sexual desire disorders.
AOD-9604 Metabolic
Reviewed AOD-9604's metabolic profile and fat-reducing properties, confirming its ability to stimulate lipolysis and inhibit lipogenesis without adverse growth hormone effects.
PT-141 Palatin
Early clinical review confirmed PT-141's novel mechanism of action through melanocortin receptors, establishing it as a groundbreaking approach to treating sexual dysfunction.
Delta sleep-inducing peptide and its tetrapeptide analogue alleviate severity of metaphit seizures
Demonstrated DSIP's anticonvulsant properties by alleviating seizure severity, revealing neuroprotective benefits beyond its established sleep-promoting effects.
Gateways to clinical trials
Featured AOD-9604's entry into clinical trials for obesity treatment, marking a significant milestone in its development as a targeted fat-reduction peptide therapy.
Bremelanotide
Profiled bremelanotide's pharmacological properties and clinical development trajectory, documenting its progression as a first-in-class melanocortin-based sexual health therapy.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Made the case for sermorelin as a superior approach to managing adult-onset growth hormone insufficiency, offering a more physiological alternative to direct GH replacement.
Obesity drugs in clinical development
Highlighted AOD-9604 among the most promising obesity drugs in clinical development, noting its unique mechanism for stimulating fat metabolism without growth hormone side effects.
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Comprehensive review explored DSIP's multifaceted neurobiological activities including stress protection, pain modulation, and sleep regulation, underscoring its untapped therapeutic potential.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Showed that once-daily CJC-1295 fully normalizes growth in GHRH-deficient models, confirming its effectiveness as a long-acting growth hormone-releasing hormone analog.
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Demonstrated bremelanotide's positive effect on subjective sexual response in premenopausal women with sexual arousal disorder, validating its mechanism for female sexual health.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Demonstrated that CJC-1295 produces prolonged elevation of growth hormone and IGF-1 in healthy adults, confirming its efficacy as a long-acting growth hormone secretagogue.
alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Positioned alpha-MSH related peptides including KPV as a new class of anti-inflammatory and immunomodulating drugs with broad therapeutic potential across autoimmune conditions.
Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent
Established thymosin beta-4 as a novel corneal wound healing and anti-inflammatory agent, demonstrating significant therapeutic potential for ocular surface disorders.
beta-Thymosins
Comprehensive review of beta-thymosins highlighted their essential roles in cell motility, angiogenesis, and wound healing, reinforcing the biological foundation for TB-500 therapy.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Demonstrated that KPV is actively transported via PepT1 to reduce intestinal inflammation, identifying a targeted mechanism for its anti-inflammatory efficacy in the gut.
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Confirmed KPV's potent anti-inflammatory effects in inflammatory bowel disease models, establishing it as a promising therapeutic peptide for IBD management.
Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore
Revealed that alpha-MSH related peptides including KPV possess powerful anti-inflammatory effects that extend beyond the traditional pharmacophore, broadening therapeutic applications.
Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model
Demonstrated that colon-targeted KPV nanoparticles effectively reduce colitis, advancing a targeted drug delivery approach for inflammatory bowel disease treatment.
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation
Successfully characterized CJC-1295's molecular identity and properties, contributing to the scientific understanding of this growth hormone-releasing peptide.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Revealed BPC-157 promotes tendon healing through multiple mechanisms including cell survival, migration, and tendon outgrowth, providing mechanistic support for its clinical use.
Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists
Elucidated KPV's mechanism for inhibiting cellular and systemic inflammation in human bronchial cells, revealing its therapeutic promise for respiratory inflammatory conditions.
Advances in the detection of growth hormone releasing hormone synthetic analogs
Reviewed analytical advances for GHRH analogs including sermorelin, reflecting the growing scientific interest in and clinical relevance of growth hormone-releasing therapies.
Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation
Demonstrated Selank's efficacy in alleviating alcohol withdrawal symptoms, supporting its therapeutic potential as a peptide-based anxiolytic for substance use recovery.
Delta-sleep inducing peptide entrapment in the charged macroporous matrices
Advanced DSIP delivery technology through macroporous matrix entrapment, improving stability and controlled release for potential sleep therapy applications.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Demonstrated GHK's role as a natural modulator of multiple cellular pathways in skin regeneration, supporting its use as a science-backed ingredient in regenerative skin care.
Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction
Showed GHK-Cu improves healing outcomes in ACL reconstruction, supporting its potential application in orthopaedic surgery and ligament repair.
LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
Comprehensive review confirmed LL-37's pleiotropic biological activities spanning antimicrobial defense, wound healing, and immune modulation, establishing it as a versatile therapeutic peptide.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
Documented real-world female use patterns of CJC-1295 for body composition and anti-aging goals, providing valuable insights into its perceived benefits and user experience.
Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
Revealed KPV's therapeutic benefits in reducing colitis-associated cancer risk through PepT1-mediated anti-inflammatory pathways, supporting its chemopreventive potential.
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
Demonstrated GHK-Cu's powerful anti-inflammatory effects in acute lung injury, highlighting its therapeutic potential for treating inflammatory respiratory conditions.
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Revealed Selank's ability to modulate GABAergic gene expression, providing molecular evidence for its anxiolytic mechanism and potential for treating neurological disorders.
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Showed Selank synergistically enhances anti-anxiety effects when combined with diazepam, suggesting it could improve outcomes in anxiety treatment protocols.
Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis
Developed a KPV-based fluorescent probe capable of distinguishing chronic from acute ulcerative colitis, advancing diagnostic precision for inflammatory bowel disease.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Demonstrated that orally delivered KPV nanoparticles efficiently alleviate ulcerative colitis, establishing a viable oral therapeutic approach for inflammatory bowel disease.
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Elucidated the molecular mechanisms underlying Selank's anxiolytic activity, confirming its unique peptide-based approach to anxiety reduction without sedation or dependency risk.
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
Demonstrated BPC-157's interactions with angiogenic growth factors across multiple tissue types, revealing its comprehensive mechanism for accelerating healing in tendons, ligaments, muscle, and bone.
Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37
Reviewed major progress in LL-37-based antimicrobial peptide design, highlighting successful modifications that enhance therapeutic potency against resistant pathogens.
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Confirmed BPC-157's significant role in accelerating musculoskeletal soft tissue healing, reinforcing its value for sports injuries and rehabilitation.
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Showed Selank protects against ethanol-induced memory impairment by regulating BDNF levels in the brain, supporting its neuroprotective and cognitive-enhancing properties.
Bremelanotide: First Approval
Documented the landmark FDA approval of bremelanotide (PT-141) as the first on-demand treatment for hypoactive sexual desire disorder in premenopausal women.
Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy
Demonstrated BPC-157's efficacy in promoting fistula healing, adding to the growing evidence of its powerful tissue repair capabilities across challenging wound types.
Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii
Demonstrated LL-37's ability to induce antibiotic sensitization in drug-resistant bacteria, offering a novel strategy for combating antimicrobial resistance.
Ternary Cu(II) Complex with GHK Peptide and Cis-Urocanic Acid as a Potential Physiologically Functional Copper Chelate
Characterized a novel GHK-copper complex with enhanced physiological functionality, expanding the understanding of copper peptide bioactivity for therapeutic applications.
Theoretical study of copper binding to GHK peptide
Elucidated the molecular mechanisms of copper binding to GHK peptide, advancing our understanding of how GHK-Cu exerts its regenerative biological effects.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Demonstrated the valuable role of growth hormone secretagogues like sermorelin in optimizing body composition in hypogonadal males, beyond traditional androgen therapy alone.
The potential of GHK as an anti-aging peptide
Demonstrated that GHK-Cu promotes skin remodeling, wound healing, and cognitive improvement in aged mice, while documenting that natural GHK levels decline significantly with age.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Comprehensive review confirmed BPC-157's remarkable wound healing properties across multiple tissue types, supporting its role as a versatile regenerative peptide.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
STEP 3 showed semaglutide combined with intensive behavioral therapy produces even greater weight loss, demonstrating the power of an integrated treatment approach.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
STEP 4 confirmed that continued semaglutide treatment is critical for maintaining weight loss, with sustained therapy preserving significantly greater reductions than placebo.
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
Demonstrated DSIP's neuroprotective capacity by recovering motor function after focal stroke, suggesting promising applications for post-stroke neurological rehabilitation.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Head-to-head trial in the NEJM demonstrated tirzepatide's superior glycemic control compared to semaglutide, establishing it as a next-generation diabetes therapy.
In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis
Demonstrated KPV's potent anti-inflammatory, antibacterial, and tissue-repairing effects when delivered via hydrogel, effectively treating chemotherapy-induced oral mucositis.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Showed that intra-articular BPC-157 injection effectively reduces multiple types of knee pain, supporting its clinical use for joint-related conditions.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
The SURPASS-1 trial confirmed tirzepatide's excellent efficacy and safety as a novel dual GIP/GLP-1 receptor agonist, achieving superior glycemic control in type 2 diabetes.
A potentially effective drug for patients with recurrent glioma: sermorelin
Identified sermorelin as a potentially effective therapeutic option for patients with recurrent glioma, expanding its clinical applications beyond growth hormone stimulation.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Landmark STEP 1 trial demonstrated that once-weekly semaglutide achieves an average 14.9% body weight reduction, establishing a new benchmark in obesity pharmacotherapy.
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Comprehensive clinical review validated bremelanotide (PT-141) as an effective treatment for hypoactive sexual desire disorder in women, supporting evidence-based prescribing.
Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent
Explored LL-37's potential as an anti-HIV agent, revealing promising antiviral activity that could lead to novel therapeutic strategies against HIV infection.
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Meta-analysis confirmed semaglutide's strong efficacy and favorable safety profile for weight loss in non-diabetic obesity, strengthening the evidence base for its widespread clinical use.
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro
Showed Epitalon provides significant protection against aging-related cellular damage, reinforcing its role as a promising anti-aging and cellular preservation agent.
Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle
Demonstrated BPC-157's protective and regenerative effects across striated, smooth, and cardiac muscle tissues, broadening its therapeutic applications for muscle recovery.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
STEP 8 trial demonstrated weekly semaglutide's superiority over daily liraglutide for weight loss, establishing it as the more effective and convenient GLP-1 therapy.
Tirzepatide Once Weekly for the Treatment of Obesity
Landmark NEJM trial showed tirzepatide produces unprecedented weight reduction of up to 22.5% in adults with obesity, setting a new standard for pharmacological weight management.
Pentadecapeptide BPC 157 and the central nervous system
Revealed BPC-157's significant neuroprotective effects on the central nervous system, supporting its therapeutic potential for neurological repair and recovery.
Medical Treatment of Female Sexual Dysfunction
Reviewed the landscape of female sexual dysfunction treatments, highlighting bremelanotide (PT-141) as an effective FDA-approved option for hypoactive sexual desire disorder.
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Demonstrated Selank's ability to attenuate morphine withdrawal symptoms, supporting its anxiolytic properties and potential as a therapeutic aid in addiction recovery.
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
The STEP 5 trial demonstrated that semaglutide maintains significant weight loss over two years, establishing long-term durability of its obesity treatment effects.
Semaglutide for the treatment of obesity
Comprehensive review affirmed semaglutide as a groundbreaking treatment for obesity, with strong evidence of sustained weight loss and cardiovascular risk reduction.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Phase 3 SURMOUNT-2 trial demonstrated significant weight loss with tirzepatide in people with obesity and type 2 diabetes, confirming its dual metabolic benefits.
LL-37 Triggers Antimicrobial Activity in Human Platelets
Revealed that LL-37 activates antimicrobial activity in human platelets, uncovering a novel immune defense mechanism with therapeutic implications for infection control.
Antibiofilm properties of cathelicidin LL-37: an in-depth review
In-depth review confirmed LL-37's powerful antibiofilm properties, positioning it as a promising candidate for combating persistent biofilm-associated infections.
The LL-37 domain: A clue to cathelicidin immunomodulatory response?
Provided new insights into LL-37's immunomodulatory domain, revealing key structural features that drive its dual antimicrobial and immune-regulating capabilities.
Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals
Demonstrated thymosin beta-4's capacity to promote healing of middle ear lesions in adult mammals, expanding its regenerative applications to otological medicine.
Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis
Identified thymosin beta-4 as a promising adjunct treatment for bacterial keratitis, highlighting its anti-inflammatory and wound-healing benefits for ocular health.
Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
Demonstrated that liposomal delivery significantly enhances GHK-Cu bioavailability for cosmetic applications, supporting advanced formulations for skin rejuvenation.
Targeting the central melanocortin system for the treatment of metabolic disorders
Highlighted the central melanocortin system as a powerful therapeutic target, reinforcing the clinical relevance of melanocortin-based peptides for metabolic and sexual health disorders.
Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Demonstrated that DSIP fusion peptides can cross the blood-brain barrier and effectively alleviate insomnia, advancing DSIP's therapeutic potential for sleep disorders.
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity
Revealed BPC-157's pleiotropic benefits extend to neurotransmitter modulation, suggesting broad neuroprotective and neuroregenerative therapeutic applications.
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
Confirmed tirzepatide's robust weight reduction efficacy across diverse populations, reinforcing its global applicability as a leading obesity treatment.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Demonstrated that continued tirzepatide treatment successfully maintains substantial weight reduction, confirming the importance of sustained therapy for long-term obesity management.
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
Showed that ipamorelin effectively inhibits chemotherapy-induced weight loss, supporting its therapeutic potential for cachexia and appetite preservation during cancer treatment.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Demonstrated tirzepatide's efficacy in treating both obesity and obstructive sleep apnea simultaneously, revealing significant multi-system health benefits beyond weight loss alone.
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Head-to-head comparison validated both semaglutide and tirzepatide as highly effective weight loss therapies, confirming the transformative impact of GLP-1 receptor agonists on obesity management.
Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications
Comprehensive review highlighted LL-37's potent antimicrobial properties and the therapeutic potential of its modified analogs for treating resistant infections.
Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development
Demonstrated that Epitalon-activated telomerase enhances cellular development and maturation, providing further evidence for its role in cellular rejuvenation and longevity research.
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
Advanced the field of GHK-Cu delivery science by exploring liposomal encapsulation for enhanced skin permeation, reinforcing GHK-Cu's value as a cutting-edge anti-aging topical therapy.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
Extensive literature and patent review confirmed BPC-157's multifunctional therapeutic profile, spanning wound healing, organ protection, and anti-inflammatory activity across multiple systems.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Systematic review confirmed BPC-157's emerging promise in orthopaedic sports medicine, with consistent evidence supporting its tissue-healing and anti-inflammatory capabilities.
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
Provided a comprehensive overview of Epitalon's bioactive properties, confirming its broad range of benefits including telomerase activation, antioxidant effects, and anti-aging potential.
Tirzepatide for Obesity Treatment and Diabetes Prevention
Showed tirzepatide effectively treats obesity while also preventing the onset of type 2 diabetes, marking a dual-benefit breakthrough in metabolic therapy.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
Demonstrated that Epitalon significantly increases telomere length in human cell lines via telomerase activation, supporting its potential as a powerful anti-aging intervention.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Provided a comprehensive primer on injectable peptide therapies for sports medicine, validating their growing clinical adoption for tissue repair and performance recovery.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Highlighted the expanding role of therapeutic peptides in orthopaedic medicine, underscoring their regenerative potential for musculoskeletal conditions and promising future clinical applications.